Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom

Journal of Infectious Diseases

Volumn 194, Issue 12, 2006, Pages 1745-1752

  Auckland, Cressida ^a   Gray, Stephen ^a   Borrow, Ray ^a   Andrews, Nick ^a   Goldblatt, David ^b   Ramsay, Mary ^a   Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; RISK FACTOR; SEROTYPE; TREATMENT FAILURE; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GREAT BRITAIN; HUMANS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; RISK FACTORS; SENTINEL SURVEILLANCE; VACCINATION; VACCINES, CONJUGATE;

EID: 33845393967     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509619     Document Type: Article

References (32)

1. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20(Suppl 1):S58-67.
2. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health 2002; 5:220-5.
3. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357:195-6.
4. Enhanced surveillance of suspected meningococcal disease. Available at: http://www.hpa.org.uk/infections/topics_az/meningo/advice/mensurvw99.pdf. Accessed 16 August 2006.
5. Trotter CL, Andrews N, Kaczmarski E, Miller E, Ramsay MEB. Effectiveness of the meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7.
6. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002; 186:1353-7.
7. Guiver M, Borrow R. PCR diagnosis. In: Pollard AJ, Maiden MCJ, eds. Meningococcal disease. Totowa, NJ: Humana Press, 2001:23-39.
8. Gray SJ, Trotter CL, Ramsay ME, et al. The epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: the contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887-96.
9. Milford Ward A. PRU handbook of clinical immunochemistry. 5th ed. Sheffield, UK: PRU Publications, 1996.
10. Burrage M, Robinson A, Borrow R, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002; 70: 4946-54.
11. Maslanka SE, Gheesling LL, LiButli DE, et al. Standardisation and a multi-laboratory comparison of Neisseria meningitidis serogroup A and C bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-7.
12. Gheesling LL, Carlone GM, Pais LB, et al. Multicenter comparison of Neisseria serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994;32:1475-82.
13. Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001; 184:377-80.
14. Borrow K, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C vaccines in the UK: re-evaluation of the correlates of protection. Infect Immun 2001; 69:1568-73.
15. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6.
16. Ramsay ME, Andrews N, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C vaccination in England: database analysis. BMJ 2003; 326:365-6.
17. Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 1977; 9:105-10.
18. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26.
19. Figueroa J, Andreoni J, Densen P. Complement deficiency states and meningococcal disease. Immunol Res 1993; 12:295-311.
20. Emonts M, Hazelzet JA, de Groot R, Hermans PW. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003; 3:565-77.
21. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure. Clin Infect Dis 2000; 31:973-80.
22. Slack MH, Cade S, Schapira D, et al. DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation. Arch Dis Child 2005;90:338-41.
23. Collins CL, Rüggeberg J, Balfour G, et al. Immunogenicity and immunological memory of meningococcal C conjugate vaccine in premature infants. Pediatr Infect Dis J 2005; 24:966-8.
24. Slack MH, Schapira D, Thwaites RJ, et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis - Haemophilus influenzae type b conjugate vaccines. J Infect Dis 2001; 184:1617-20.
25. Berrington JE, Cant AJ, Matthews JN, O'Keefe M, Spickett GP, Fenton AC. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics 2006; 117: e717-24. Electronically published 20 March 2006.
26. Trotter C, Fox AJ, Ramsay ME, et al. Fatal outcome from meningococcal disease - an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. J Med Microbiol 2002; 51:855-60.
27. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5.
28. Ramsay ME, Miller E, Andrews N, Slack M, Heath P. Epidemiological data are essential. Available at: http://bmj.bmjjournals.com/cgi/eletters/bmj.38301. 657014.79v1#89318. Accessed 15 August 2006.
29. McVernon J, Johnson PD, Pollard A, et al. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 2003; 88:379-83.
30. Borrow R, Miller E. Surrogates of protection. In: Frosch M and Maiden M, eds. Handbook of meningococcal disease. London: Wiley-CH, 2006: 323-51.
31. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003; 361:1523-4.
32. Chief Medical Officer, Chief Nursing Officer, Chief Pharmacist. Important changes to the Childhood Immunisation Programme. Department of Health, 7 December 2006.